Background In drug development, animal toxicology data are very important for the evaluation of clinical safety. We quantitatively assessed the safety profiles of blood cancer drugs approved in Japan from category I (high) to V (low). We examined the ratios of drug exposure in animals at the no observed adverse effect level to those in humans at the expected therapeutic dose. In addition, qualitative analysis of the relationship between toxicological findings and adverse drug reactions (ADRs) is one of the primary approaches for determining the risk-benefit profile of a pharmaceutical. This study thus aimed to evaluate the potential of nonclinical safety assessments for predicting ADRs in humans. Methods We examined toxicological findings at the lowest observed adverse effect level and ADRs in pivotal clinical studies. We calculated concordance rates as the ratio of the number of concordant ADRs to all ADRs. Results Twenty-seven drugs were eligible for analysis. Concordance rates ranged from 0 to 84.8%. No significant differences were observed in concordance rates between antibodies (median 14.3%) and small molecules (median 18.5%). There was a significant correlation between concordance rates and quantitative safety profiles (p = 0.047), suggesting that some drugs with low safety profiles (categories III, IV, or V) have high concordance rates. Conclusion The results suggested that ADRs in clinical trials could be predicted based on toxicity data obtained in animal tests, especially for some drugs with a low quantitative safety profile.
Introduction
Nonclinical data play a fundamental role in new drug development; they can be used to assess potential safety risks. The International Conference on Harmonisation (ICH) M3(R2) recommends that nonclinical safety studies should be adequate to characterize potential adverse effects & Sachie Kubota dp14-002@jiu.ac.jp that might occur under the conditions of the clinical trial to be supported [1] . It also states that clinical trials defined by ICH E8 should be extended based on the demonstration of adequate safety in previous clinical trial(s), as well as on additional nonclinical safety information [1, 2] . Human pharmacology studies with biomarkers conducted at the early clinical phases do not play a key role for safety estimation in therapeutic exploratory and/or therapeutic confirmatory studies in Japanese new drug applications (NDAs) [3] ; therefore, animal toxicology data are useful for the prediction of safety profiles during the late clinical phases.
As one of the primary measures for determining the risk-benefit profile of a pharmaceutical, we recently conducted a study to evaluate the quantitative safety profiles of blood cancer drugs approved in Japan [4] . We examined safety indices obtained using the ratio of drug dose/exposure in animals at the no observed adverse effect level (NOAEL) to that in humans at the expected therapeutic dose. We used data from toxicokinetic studies indispensable for safety assessment as stated in ICH S3A [5] . We categorized quantitative safety profiles into five types, from I (high) to V (low), and found that although there were some drugs for blood cancer treatment with low quantitative safety profiles (categories III, IV, and V), the safety profiles of those drugs were not discussed in the NDA dossiers [4] . In the regulatory reviews for drug approval, quantitative safety profiles can provide a certain amount of information for the evaluation of the risk-benefit balance. In addition, it is important to assess drug safety using qualitative aspects by comparing nonclinical toxicology findings and adverse drug reactions (ADRs). However, there have been relatively few attempts to methodically assess the correlation between toxicity levels caused by the same drugs in animals and humans.
Igarashi et al., at the Japanese Pharmaceutical Manufacturers Association (JPMA), investigated published papers on general pharmacological studies and the clinical adverse reactions observed during new drug development [6] . They demonstrated that tests of cardiovascular functions, spontaneous locomotor activity, and intestinal transport are of considerable value in predicting ADRs. Furthermore, Olson et al. revealed that 71% of ADRs were observed in animals for the same target organ and the hematological, gastrointestinal, and cardiovascular ADRs were highly concordant [7] . However, evidence supporting the prediction of or extrapolation to human toxicities from the results of animal toxicology studies is scarce, and there is no consensus on this matter. Against this background, our primary objective in this study was to evaluate the potential of nonclinical safety assessments for predicting ADRs in humans treated with blood cancer drugs.
Methods

Data Source
We first reviewed data from drugs for blood cancer because severe adverse reactions were observed during clinical development and post-marketing surveillance of anticancer drugs. Moreover, the number of new molecular entities (NMEs) in this therapeutic area was suitable for this examination as a starting point and this group contained not only small-molecule drugs but also macromolecular drugs such as antibody drugs. Drugs for blood cancer approved in Japan from September 1999 to November 2016 as NMEs were analyzed. NOAEL, maximum approved dose, exposure levels at NOAEL and maximum approved dose, lowest observed adverse effect level (LOAEL), toxicological findings obtained at LOAEL, and ADRs were extracted from NDA review reports by the Ministry of Health, Labor and Welfare (MHLW) (until March 2004), the Pharmaceuticals and Medical Devices Agency (PMDA) (from April 2004), the common technical document (CTD) [8] by marketing authorization holders, package inserts, and interview forms available on the PMDA website [27] . Data were obtained in accordance with Japanese domestic regulations such as Good Clinical Practice [9] and Good Laboratory Practice [10] guidelines complying with the Pharmaceutical Affairs Law. Of the 539 NMEs identified, 28 drugs for blood cancer were identified for analysis (Table 1) .
Data Handling
Safety Index
Safety indices are obtained from the ratio of doses and exposure levels in animals to those in humans. The safety index by dose (SI-D), safety index by maximum plasma [4] . SI-D = NOAEL (mg/kg/day)/maximum approved dose (mg/kg/day) SI-C = C max at NOAEL (lg/mL)/C max at maximum approved dose (lg/mL) SI-A = AUC at NOAEL (lgÁh/mL)/AUC at maximum approved dose (lgÁh/mL).
Quantitative Safety Profile
The quantitative safety profile of each drug was assessed if both SI-D and SI-C or SI-A were available. The safety profiles fell into five categories based on the safety indices ( These categories comprise one approach to clarify safety characteristics including the balance between safety index by dose and that by exposure. Safety profile I shows that both dose and exposure levels for animals exceed those for humans; therefore, it is interpreted that there is a certain safety margin for a drug categorized in safety profile I, while a drug in safety profile V has no safety margin for either dose or exposure levels. [4] , that is, the study that gave the smallest NOAEL. To compare the toxicological findings with ADRs, names and the number of ADRs of Cgrade 3 were obtained from the clinical studies defined as pivotal. The grades were based on National Cancer Institute-Common Toxicity Criteria Version 2.0 [11] , Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 [12] , and CTCAE Version 4.0 [13] . In cases where the grades of severity were categorized as mild, moderate, and severe, the severe grade was considered to be Cgrade 3. Prioritization of pivotal studies used for analysis is shown in Table 2 . We placed the utmost importance on studies with Japanese patients. If phase III data of Japanese patients were not obtained, phase II studies with Japanese patients were selected. In the case that no Japanese patient data were available other than a phase I study, foreign clinical data for which extrapolation to the Japanese population had been accepted based on ICH E5 [14] were used. As there was one drug (gemtuzumab ozogamicin) for which ADRs were not available in the source documents, adverse events (AEs) were substituted for ADRs. 
Concordance of ADRs and Toxicological Findings
An ADR reported in a clinical study was considered concordant with a nonclinical toxicological finding when the same finding was made in a human and an animal, or similar observations were made for similar organs [6, 7, 15, 16] (Table 3) . Concordance rate was calculated as follows:
Drugs for Which Toxicological Findings at LOAEL
Are Available Concordance rate (%) = (number of ADRs or AEs of Cgrade 3 that are concordant with toxicological findings at LOAEL/total number of ADRs or AEs of Cgrade 3) 9 100.
Are Not Available Concordance rate (%) = (number of ADRs or AEs of Bgrade 1 that are concordant with nontoxic observations at NOAEL/total number of ADRs or AEs of Bgrade 1) 9 100.
Statistical Analysis
The SPSS software Version 23 (IBM, Armonk, NY, USA) was used to perform statistical analysis of the collected data. Comparisons were performed by the Mann-Whitney U test. Regarding the association between two variables measured on at least an ordinal scale, the Spearman rankorder correlation coefficient was used. A p value of \0.05 was considered statistically significant.
Results
Of the 28 drugs for blood cancer, 27 were eligible for analysis. Ibritumomab tiuxetan was excluded because the lack of data prevented calculation of the safety index. NOAEL, LOAEL, and clinical studies selected for the analysis are listed in Table 4 . Table 5 shows the concordance rate, administration route, drug type, species, and quantitative safety profile for each drug. The concordance rate of bosutinib was not calculated because of the lack of information on the severity of ADRs. The concordance rate of each System Organ Class (SOC) categorized by CTCAE is listed in Table 6 . ADRs that were concordant with nonclinical observations in blood lymphatic system disorders and investigations were observed for many drugs, that is, 16 and 15 out of 26 drugs, respectively. The mean concordance rate of 26 drugs excluding bosutinib was 23.9% (median: 18.5%), with a range of 0-84.8%. When stratified by the drug type, the mean concordance rates of small-molecule drugs and antibody drugs were 24.1% (median 18.5%) and 23.3% (median 14.3%), respectively. There was no significant difference between them (p = 0.839; Fig. 2 ). The mean concordance rates of drugs with nonclinical data for rodents, non-rodents, oral drugs, and injectable drugs were 24.7% (median 24.3%), 23.6% (median 16.7%), 16.4% (median: 6.8%), and 31.4% (median 21.8%), respectively (Table 5) . No significant differences between concordance rates were observed based on species (rodent vs. non-rodent; p = 0.935) and administration route (p = 0.169).
The mean concordance rates of drugs excluding bosutinib by quantitative safety profile [five types; from I (high) to V (low)] were 7.4% (I), 18.4% (III), and 37.0% (V) ( Table 5 ). (No drug was categorized into II in this study. Bosutinib was categorized into IV, but its concordance rate was not calculable.) The concordance rate and quantitative safety profile were weakly correlated (Spearman's r = 0.448, p = 0.047; Fig. 3 ). ADRs adverse drug reactions, RBC red blood cell, WBC white blood cell, : increased, ; decreased [6] . They showed that general pharmacological studies of cardiovascular functions, spontaneous locomotor activity, and intestinal transport were useful in predicting ADRs [6] . More recently, Tamaki et al. conducted a study to examine the usefulness of nonclinical safety assessments in predicting ADRs in humans [17] . They revealed that 37% of ADRs were predictable based on concordant toxicological findings in animals [17] . This figure is slightly higher than the mean concordance rate of our study (23.9%). However, considering that they targeted all drugs, excluding anticancer agents and vaccines, and collected ADRs with an incidence rate of C5%, these figures are comparable.
In a further investigation, we analyzed the correlation between the concordance rate and the quantitative safety profile obtained in our previous study [4] . As shown in Fig. 3 , there was a significant correlation between these ADRs adverse drug reactions, AEs adverse events, AUC area under the plasma concentration-time curve, C max maximum plasma concentration, NA not available, NOAEL no observed adverse effect level, SD standard deviation, SM small molecule a Animal species that gives the smallest NOAEL b SI-D = NOAEL (mg/kg/day)/the maximum approved dose (mg/kg/day) c SI-C = C max at NOAEL (lg/mL)/C max at the maximum approved dose (lg/mL) d SI-A = AUC at NOAEL (lgÁh/mL)/AUC at the maximum approved dose (lgÁh/mL) e Concordance rate (%) = (number of ADRs or AEs of Cgrade 3 that are concordant with toxicological findings at LOAEL/total number of ADRs or AEs of Cgrade 3) 9 100 f Concordance rate (%) = (number of ADRs or AEs of Bgrade 1 that are concordant with nontoxic observations at NOAEL/total number of ADRs or AEs of Bgrade 1) 9 100 g Excluding bosutinib We found that the median concordance rate of antibody drugs (14.3%) was lower than that of small-molecule drugs (18.5%), although there was no significant difference between them and the number of antibodies was small. Tamaki et al. reported that the proportion of correlated ADRs in small-molecule drugs was 46% and that in antibody drugs was 16%, indicating a trend similar to that of our results [17] . For small molecules, general toxicology tests are usually performed in rodents and non-rodents (ICH S9) [18] . However, ICH S6 [19] states that safety evaluation programs for biotechnology-derived pharmaceuticals should normally include two relevant species, but in certain justified cases, one relevant species may suffice. According to the ICH S6 guideline, the animal species for testing of monoclonal antibodies are those that express the desired epitope and demonstrate a similar tissue cross-reactivity profile as for human tissues.
In our study, four of the six antibody drugs had nonclinical data only for monkeys, and other species were not investigated. This might have contributed to the low concordance rate. Chapman et al. discussed the selection of species for toxicology studies of monoclonal antibodies [20] . They raised the concern that species cross-reactivity alone might not be sufficient to confirm species suitability. They referred to the case of TGN412, an anti-CD28 superagonist monoclonal antibody, which induced a life-threatening cytokine storm in its first human study. Although there was no significant difference in concordance rates between antibody and small-molecule drugs, an appropriate way to predict the risk to humans, based on nonclinical toxicity findings for antibody drugs, is still needed. In 2014, seven of the top ten best-selling drugs in the world were biotechnology-derived pharmaceuticals [21] and many more biopharmaceutical products are under development [22] . Therefore, practical guidance for a risk-benefit assessment of biopharmaceuticals would be beneficial.
There is currently no established method to weigh the predictability of ADRs in humans on the basis of animal data. Bailey et al. conducted several studies on human drug safety using toxicity data obtained from animal tests [23] [24] [25] . They suggested that toxicity observed in animals occurs in humans. However, their data were not particularly consistent or reliable because of considerable variability and the lack of any clear pattern in the types of toxic effects. They overlooked the caveat that the absence of toxicity in animals provided essentially no insight into the likelihood of toxicity or absence of toxicity in humans. Perel et al. compared treatment effects reported in systematic reviews of clinical trials with those of their own systematic review of the corresponding animal experiments [26] . They concluded that many animal studies are of poor methodological quality and the lack of concordance between animal experiments and clinical trials is the result of bias, random error, or the failure of animal models to adequately represent human diseases.
Although we investigated all blood cancer drugs approved in Japan from 1999 to date, there is a limitation in publicly available data. Access to some of the existing data was not possible because study reports in CTD M4 and M5 were not disclosed; only summary documents, such as CTD M2, are available. The amount of information available for different drugs varies; some CTD M2 documents contain enough data for analysis but others do not. Moreover, as we focused on drugs for blood cancer, caution should be taken when generalizing about drugs used in other therapeutic areas.
We found that the potential range of applications of nonclinical assessments in ADR predictions was substantial. However, our concordance rates differed from those reported in some other studies. Our analysis of the relationship between concordance rate and quantitative safety profile found a weak correlation, suggesting that ADRs are predictable on the basis of animal toxicities, especially for some drugs with low quantitative safety profiles. Perel et al. suggested that with the increasing number of systematic reviews of animal experiments, a quantitative approach to determine similarities between animal models and clinical trials should become possible [26] . Our study results should contribute to the development of this field.
Conclusion
Within the constraints of this study, our results suggest that toxicity findings observed in animal tests could be extrapolated to human treatments. This might allow the prediction of ADRs in clinical trials for some drugs with a low quantitative safety profile. Nonclinical safety assessments might be useful in predicting the clinical safety of such drugs.
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